Will Biogen walk-the-talk and do another natalizumab SPMS trial?

At #MSParis207 I presented a new analysis of the data of the ASCEND trial (natalizumab in SPMS) that shows natalizumab is very effective in protecting upper limb function, and to a lesser extent lower limb function, in people with more advanced MS (majority needing walking aids). 



Will Biogen learn from this analysis and do an ASCEND-2 trial? If they cared about people with more advanced MS they would do this study. I also anticipate that in the future PML will not be a problem; we will have antivirals that will clear the body of JCV and the risk of PML as a complication of natalizumab treatment will become very, very, low. The latter is another reason for doing this study.

YouTube Webinar:

SlideShare slides: 

ProfG    

Are we on the cusp of a self-monitoring revolution?

Self-monitoring and the socialisation of web-based apps is the revolution waiting to happen in MS care.

The following is my 'Hot Topics' talk on web-based PROMS (patient-related outcome measures). The presentation should be self-explanatory but if you have any questions please feel free to ask.

ProfG